Standout Papers

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre... 2020 2026 2022 2024308
  1. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study (2020)
    Gilles Salles, Johannes Duell et al. The Lancet Oncology

Immediate Impact

6 by Nobel laureates 24 from Science/Nature 59 standout
Sub-graph 1 of 22

Citing Papers

Diffuse Large B-Cell Lymphoma
2021 Standout
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
1 intermediate paper

Works of Zsolt Nagy being referenced

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
2020 Standout
Analysis of circulating microRNAs in adrenocortical tumors
2013
and 1 more

Author Peers

Author Last Decade Papers Cites
Zsolt Nagy 1536 873 863 280 5.6k
Masaki Ueno 1203 626 562 183 5.3k
Kazuo Umemura 1561 728 426 365 6.6k
Hongwei Qin 1665 967 1147 268 9.3k
Jian Luo 2232 1140 383 118 6.9k
Xiaojun Zhang 1705 315 482 365 7.0k
Kenji Sugiyama 1067 270 499 220 4.9k
Hiroshi Onodera 1848 1078 326 201 5.5k
Hiroshi Oka 2390 444 1196 332 6.9k
Seung‐Koo Lee 802 655 486 378 9.6k
Yanfeng Wang 3292 654 760 296 10.3k

All Works

Loading papers...

Rankless by CCL
2026